Isis Pharmaceuticals, Inc. Press Releases

Isis Pharmaceuticals to Present at the 2013 UBS Global Healthcare Conference
05/13/2013 7:00AM - PR Newswire

Isis Pharmaceuticals Earns $3.5 Million from Biogen Idec
05/09/2013 4:34PM - PR Newswire

Isis Pharmaceuticals to Present at the Bank of America Merrill Lynch 2013 Health Care Conference
05/09/2013 2:39PM - PR Newswire

Isis Pharmaceuticals Prices Public Offering Of Common Stock
05/08/2013 9:50PM - PR Newswire

Isis Pharmaceuticals Announces Proposed Public Offering of Common Stock
05/07/2013 4:08PM - PR Newswire

Isis Reports Financial Results and Highlights for First Quarter 2013
05/07/2013 4:05PM - PR Newswire

Isis Pharmaceuticals Announces the Initiation of a Clinical Study of ISIS-STAT3 Rx in Patients with Liver Cancer
05/06/2013 7:00AM - PR Newswire

Webcast Alert: Isis Pharmaceuticals' First Quarter 2013 Financial Results Conference Call
05/02/2013 12:58PM - PR Newswire

ISIS Pharmaceuticals Initiates a Clinical Study of ISIS-SMN Rx in Infants With Spinal Muscular Atrophy
04/23/2013 7:00AM - PR Newswire

Isis Pharmaceuticals to Present at the 12th Annual Needham Healthcare Conference
04/22/2013 5:13PM - PR Newswire

Roche and Isis Pharmaceuticals form alliance for Huntington's disease
04/08/2013 9:00AM - PR Newswire

Isis Initiates Phase 1 Study of ISIS-APOA Rx to Treat Atherosclerosis
04/03/2013 7:00AM - PR Newswire

Isis Publishes Data Demonstrating Antisense Targeting of ApoC-III Significantly Reduces ApoC-III and Triglycerides
04/01/2013 7:00AM - PR Newswire

Isis Provides Update on CHMP Opinion on KYNAMRO™ (mipomersen)
03/22/2013 2:30PM - PR Newswire

Data From ISIS-SMN Rx Phase 1 Study in Children With Spinal Muscular Atrophy Presented at the American Academy of Neurology Meeting
03/20/2013 7:13PM - PR Newswire

Isis Pharmaceuticals to Present at the 25th Annual ROTH Conference
03/15/2013 7:00AM - PR Newswire

Isis Pharmaceuticals to Host Investor Event to Discuss ISIS-SMN Rx Data Presented at 2013 AAN Annual Meeting
03/14/2013 11:00AM - PR Newswire

Isis Pharmaceuticals Reports Clinical Data Showing Blunting of Severe Increases in CRP Following Endotoxin Challenge With ISIS-CRP Rx
03/13/2013 8:00AM - PR Newswire

A forward Look into the Year Ahead - Research Report on Boyd Gaming Corporation, Ameristar Casinos, Inc., Aegerion Pharmaceuticals, Inc., ISIS Pharmaceuticals, Inc. and Avon Products, Inc.
03/12/2013 8:00AM - PR Newswire

New Programs Designed to Speed Up Approval Process a Key Factor in Biotech Industry's Growth in 2012
03/07/2013 8:20AM - Market Wire

Pipeline Initiatives, Partnerships to Drive Growth - Research Report on Pfizer, Theravance, ISIS Pharmaceuticals, Infinity Pharmaceuticals and Ironwood
03/07/2013 8:00AM - PR Newswire

Isis Pharmaceuticals to Present at the Barclays Global Healthcare Conference
03/06/2013 7:00AM - PR Newswire

Isis Reports Financial Results and Highlights for 2012
02/28/2013 8:30AM - PR Newswire

Isis Pharmaceuticals To Present At The Cowen and Company 33rd Annual Health Care Conference
02/27/2013 7:00AM - PR Newswire

Isis Pharmaceuticals Initiates Phase 2 Study Of ISIS-CRP Rx In Patients With Atrial Fibrillation
02/26/2013 8:00AM - PR Newswire